Skip to main content

Current News

Comunicados de Imprensa

5 agosto, 2019

Vida Pharmacal Delivers First Treatment for Canine Chagas Disease

Author: Roy Madigan

Vida Pharmacal today announced the first cure for canine Chagas disease. Its multicenter field study, Successful Treatment of Canine Chagas Disease, was published in the prestigious Journal of the American Veterinary Medical Association, August 1, 2019.

23 março, 2018

New Company, Vida Pharmacal, Formed to Develop Treatment for Chagas Disease

Authors: Roy Madigan, Roy Madigan

Vida Pharmacal, the first pharmaceutical company devoted to developing, marketing, and distributing a treatment for Chagas disease in veterinary patients, today announced its official launch.

Papers

The effects of formulation on the pharmacokinetics of itraconazole and amiodarone in dogs after oral administration of a combination product, commercial products, and compounded products

Published on outubro 11, 2023

Vida teamed in a study that evaluated four different formulations of itraconazole and amiodarone. The study was published in the Wiley Journal of Veterinary Pharmacology and Therapeutics.

read more

PCR Monitoring of Parasitemia During Drug Treatment for Canine Chagas Disease

Published on agosto 5, 2019

Vida Pharmacal participated in a study that monitored its treatment effectiveness using two real-time assays. Published in Sage Journals, August 5, 2019.

read more

Investigation of a combination of amiodarone and itraconazole for treatment of American trypanosomiasis (Chagas disease) in dogs, JAVMA

Published on agosto 1, 2019

The purpose of the study reported here was to evaluate the clinical, serologic, parasitological, and histopathologic outcomes of dogs naturally infected with T cruzi and treated with a combination of itraconazole and amiodarone for 12 months.

read more